GlassScriptPhysician profile
Allison Williams
NPI 1821055799
$2,198.56
in general payments reported to CMS, 2019-2025
25 companies · $792 in 2025
The $792 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $110 · 2023: $379 · 2024: $793 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,963.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $706.67 | 2021-2025 | |
| Lilly USA, LLC | $285.89 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $239.77 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $155.58 | 2023-2025 | |
| Abbott Laboratories | $132.90 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Merck Sharp & Dohme LLC | $71.05 | 2023-2025 | Gardasil 9, Capvaxive, Verquvo |
| Janssen Pharmaceuticals, INC | $52.77 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.20 | 2023-2025 | Jardiance |
| Exact Sciences Corporation | $48.68 | 2023-2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $47.29 | 2024 | Voquezna |
| Hologic Sales and Service, LLC | $42.34 | 2021-2023 | Aptima, Thinprep 2000 Processor |
| E.R. Squibb & Sons, L.L.C. | $34.54 | 2021-2023 | Eliquis |
| Lundbeck LLC | $34.22 | 2023-2025 | Rexulti |
| Aimmune Therapeutics, INC. | $34.22 | 2024-2025 | Zenpep |
| Teva Pharmaceuticals USA, INC. | $33.91 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.34 | 2024-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $29.18 | 2024 | Airsupra, Farxiga |
| Daiichi Sankyo INC. | $28.45 | 2023 | Injectafer |
| Sanofi-Aventis U.S. LLC | $26.94 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $22.27 | 2025 | Rexulti |
| Organogenesis INC. | $21.05 | 2023 | Puraply |
| Dexcom, INC. | $20.18 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $18.08 | 2025 | Trelegy Ellipta |
| Currax Pharmaceuticals LLC | $14.63 | 2025 | Onzetra Xsail, Contrave |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.41 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.